Peri-treatment Creatinine-Based eGFR Trajectories in Patients Receiving Breast Radiotherapy: A Retrospective Cohort Study
The Oncologist · 04.11.2026
DOI: 10.1093/oncolo/oyag432 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Oncologist, online erschienen am 04.11.2026. Verfasst von Yunan Qing und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Glomerular Filtration Rate, Creatinine. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science and Technology Major Project for Noncommunicable Chronic Diseases.
Abstract (Originalsprache)
Background
Longitudinal estimated glomerular filtration rate (eGFR) changes during breast cancer treatment remain incompletely characterized. We examined peri-treatment eGFR trajectories, factors associated with eGFR decline, whether 1-month eGFR change was associated with later decline, and differences by radiotherapy fractionation. Materials and methods We retrospectively included 741 patients receiving breast radiotherapy from 2023 to 2025. eGFR was assessed at baseline and 1, 3, 6, 9, and 12 months. The primary endpoint was a ≥ 20% decrease from baseline confirmed at 2 consecutive scheduled visits; ≥30% decrease was the sensitivity endpoint. Trajectories were analyzed with a five-segment linear mixed-effects model. Cox regression evaluated associated factors, a temporally separated 1-month landmark analysis assessed later decline, and fractionation comparisons used multivariable adjustment and overlap weighting.
Results
58 patients (7.8%) met the confirmed ≥20% endpoint and 24 (3.2%) met the ≥30% endpoint. Trajectories diverged most clearly within 3 months. N1–3 disease (HR, 2.60; 95% CI, 1.11–6.12) and recorded CDK4/6 inhibitor use (HR, 8.73; 95% CI, 4.68–16.27) were associated with the endpoint. One-month eGFR decline was not associated with subsequent confirmed ≥20% decline (HR, 1.04 per 10% decline; 95% CI, 0.77–1.41; P = 0.786) but was associated with subsequent confirmed ≥30% decline (HR, 1.61; 95% CI, 1.06–2.44; P = 0.025). No significant renal-risk difference was observed by fractionation scheme.
Conclusion
Peri-treatment creatinine-based eGFR trajectories diverged early in patients who later met the confirmed-decline endpoint. Nodal stage and recorded CDK4/6 inhibitor use were associated with the endpoint; 1-month eGFR change was associated with the ≥30% sensitivity endpoint.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
- NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
- Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Guangzhou 510080, China.
- Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
ORCID-Profile: Xiao Yang, Mengzhen Min
Förderung
- National Science and Technology Major Project for Noncommunicable Chronic Diseases
Zitieren
APA
Qing, Y., Guo, J., Fan, L., Ouyang, B., Pan, Z., Wu, Z., Chen, R., Yang, X., & Min, M. (2026). Peri-treatment Creatinine-Based eGFR Trajectories in Patients Receiving Breast Radiotherapy: A Retrospective Cohort Study. The Oncologist. https://doi.org/10.1093/oncolo/oyag432
Vancouver
Qing Y, Guo J, Fan L, Ouyang B, Pan Z, Wu Z, et al. Peri-treatment Creatinine-Based eGFR Trajectories in Patients Receiving Breast Radiotherapy: A Retrospective Cohort Study. The Oncologist. 2026. doi:10.1093/oncolo/oyag432
BibTeX
@article{Qing2026,
author = {Qing, Yunan and Guo, Jing and Fan, Li and Ouyang, Bin and Pan, Zhenzhao and Wu, Zhaojun and Chen, Ruiwan and Yang, Xiao and Min, Mengzhen},
title = {Peri-treatment Creatinine-Based eGFR Trajectories in Patients Receiving Breast Radiotherapy: A Retrospective Cohort Study},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag432}
}
EUVIMED